Analysts await Opko Health Inc (NASDAQ:OPK) to report earnings on May, 09 for the fiscal quarter ending Mar 2016.

They expect $-0.03 EPS, up 166.67% or $0.05 from last year’s $-0.08 per share.

At the moment 6 analysts are watching Opko Health Inc (NASDAQ:OPK), 1 rate it “Buy”, 3 “Outperform”, 2 “Underperform”, 0 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Jun-16, 5 analysts have a mean sales target of 286.29 million. For the quarter ending Sep-16, 5 analysts have a mean sales target of 302.13 million whilst for the year ending Dec-16, 6 analysts have a mean target of 1,148.21 million.

In terms of earnings per share, 5 analysts have a -0.01 EPS mean target for the quarter ending Jun-16, for the quarter ending Sep-16, 5 analysts have a 0.00 EPS mean target and for the quarter ending Sep-16 there are 6 estimates of -0.05 EPS.

The biggest institutional shareholders in Opko Health Inc include Frost Phillip MD Et AL which owns 184 million shares in the company valued at $3.02 B million. Frost Gamma Investments Trust is the second biggest holder with 175 million shares currently valued at 2.48 B million whilst Vanguard Group Inc has 22 million shares valued at 220.16 million.

Total shares held by institutions as of the most recent company filings are 485,830,448 with a reported 35,429,784 bought and 14,422,007 sold. These holdings make up 89.01% of the company’s outstanding shares.

Currently insiders hold 37,823,722 shares in the business which makes up 6.93% of shares. The biggest holder currently is Dr. Jane H. Hsiao, PhD who owns 24,600,633 shares (4.51% of those outstanding), whilst Steven D. Rubin holds 5,557,489 (1.02% of shares outstanding) and Dr. Subbarao Uppaluri,PhD holds 3,822,869 (0.70% of shares outstanding).

The stock decreased 0.21% or $0.02 during the last trading session, hitting $10.05. Opko Health Inc (NASDAQ:OPK) has risen 1% over the past 6 months and is uptrending.